Skip to content
Search

Latest Stories

SBI reports 80 per cent surge in Q4 net profit

SBI reports 80 per cent surge in Q4 net profit

INDIA’S biggest bank, the State Bank of India (SBI), has reported an increase of 80 per cent in standalone net profit at Rs 64.51 billion (£624.67 million) for the fourth quarter ended March 2021.

Increase in net profit was helped by decline in bad loans and higher interest income.


The bank registered a profit of Rs 35.80 billion (£346.68 million) during January-March period of 2019-20.

Net NPA or bad loans came down to 1.50 per cent as on March 31, 2021 from 2.23 per cent in the year-ago period, it said in a regulatory filing on Friday (21).

The lender reportedly received nearly Rs 40 billion (£387.32 million) as part of dues owed by bankrupt steelmaker Bhushan Power and Steel.

In March, JSW Steel acquired Bhushan Power and Steel and implemented the resolution plan for the company where SBI was the lead banker.

Total income of the lender during the March quarter of the last financial year rose to Rs 813.27 billion (£787.9 million), from Rs 760.27 billion (£736.77 million) in the same period of 2019-20.

On a consolidated basis, the bank reported a 60 per cent increase in net profit at Rs 72.70 billion (£70.43 million) compared to Rs 45.57 billion (£44.15 million) in the fourth quarter of the previous fiscal.

For the entire financial year 2020-21, the bank reported a 41 per cent jump in standalone profit at Rs 201.10 billion (£194.83 million), from Rs 144.88 billion (£140.42 million) in the previous financial year.

The central board of the bank has also declared a dividend of Rs. 4.00 (£0.04) per equity share for the financial year ended 31st March, 2021. This is the first payout by SBI since May 2017, when it had rewarded shareholders with Rs. 2.6 (£0.03) per share.

The bank has fixed June 18, 2021 as the date of payment of dividend.

Shares of SBI closed at Rs 401.10 per unit, up 4.3 per cent on the Bombay Stock Exchange (BSE) today.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less